Form 4: Tarsus Pharmaceuticals Director Reports Routine Equity Compensation and Stock Acquisition

Scott W. Morrison, a Director at Tarsus Pharmaceuticals, Inc., has reported the acquisition of common stock through RSU settlement and new grants of stock options and Restricted Stock Units as part of his compensation.

Summary

• Scott W. Morrison, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported several equity transactions.
• On June 13, 2025, Mr. Morrison acquired 3,350 shares of Common Stock directly, resulting from the settlement of previously vested Restricted Stock Units (RSUs).
• Following this transaction, Mr. Morrison directly owns 3,350 shares of Common Stock and indirectly owns 6,016 shares through the Morrison-Minton Family 2004 Trust.
• On June 12, 2025, Mr. Morrison was granted 4,540 stock options with an exercise price of $40.95 per share, which are set to vest in full on June 12, 2026, and expire on June 11, 2035.
• Additionally, on June 12, 2025, he was granted 2,954 Restricted Stock Units (RSUs), which will vest in full on June 12, 2026.
• The 3,350 RSUs settled on June 13, 2025, were originally granted on June 13, 2024, and vested on their one-year anniversary.

Sentiment

Score: 6

Explanation: The filing details routine equity compensation grants and the settlement of vested Restricted Stock Units for a non-employee director, which is a standard practice to align director interests with shareholders. This is generally viewed as a neutral to slightly positive event.

Positives

• Director Scott W. Morrison received new equity compensation in the form of 4,540 stock options and 2,954 Restricted Stock Units (RSUs) on June 12, 2025, aligning his interests with shareholders.
• The settlement of 3,350 vested RSUs into common stock on June 13, 2025, increases the director's direct ownership in the company.

Future Outlook

The document indicates future vesting events for the newly granted stock options and Restricted Stock Units, with full vesting expected on June 12, 2026, subject to continuous service.

Industry Context

This Form 4 filing reflects routine equity compensation practices for non-employee directors in the pharmaceutical industry, aiming to align their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic oversight.

Next Steps

• The 4,540 stock options granted on June 12, 2025, are expected to vest in full on June 12, 2026.
• The 2,954 Restricted Stock Units (RSUs) granted on June 12, 2025, are expected to vest in full on June 12, 2026.

Key Dates

Keywords

Tarsus Pharmaceuticals, TARS, SEC Form 4, Insider Transaction, Director Compensation, Stock Options, Restricted Stock Units, Equity Grant, Beneficial Ownership